EAM Investors’s Palvella Therapeutics PVLA Stock Holding History

EAM Investors’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.88M	Sell	18,849 -10,479	-36%	-$1.27M	0.26%	161
2026 Q1	$3.66M	Buy	+29,328	New	+$3.06M	0.42%	110
2021 Q4	–	Sell	-3,606	Closed	-$1.49M	–	393
2021 Q3	$1.49M	Hold	3,606	–	–	0.25%	201
2021 Q2	$1.1M	Buy	+3,606	New	+$791K	0.17%	283
2018 Q2	–	Sell	-6,518	Closed	-$3.56M	–	362
2018 Q1	$3.56M	Buy	6,518 +5,198	+394%	+$3.22M	0.59%	39
2017 Q4	$797K	Sell	1,320 -749	-36%	-$348K	0.14%	234
2017 Q3	$953K	Hold	2,069	–	–	0.13%	236
2017 Q2	$837K	Sell	2,069 -215	-9%	-$62.8K	0.14%	219
2017 Q1	$475K	Buy	+2,284	New	+$404K	0.07%	296

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

EAM Investors's PVLA Position: Q2 2026 in Review

EAM Investors reduced its Palvella Therapeutics (PVLA) stake by 36% in Q2 2026, selling an estimated $1.27M and leaving 18,849 shares worth $2.88M. The position accounts for 0.26% of the portfolio, ranked #161.

EAM Investors first reported a position in PVLA in Q1 2017 and has held it in 9 quarters since. The position peaked at $3.66M in Q1 2026. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

EAM Investors held 18,849 shares of Palvella Therapeutics worth $2.88M as of Q2 2026.
EAM Investors sold 10,479 Palvella Therapeutics shares in Q2 2026, an estimated $1.27M.
Palvella Therapeutics made up 0.26% of EAM Investors's portfolio in Q2 2026, its #161 holding.
EAM Investors first reported a position in Palvella Therapeutics in Q1 2017 and has held it in 9 quarters since.
EAM Investors's Palvella Therapeutics position peaked at $3.66M in Q1 2026.
197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.